Ligand Buys Xoma for $740M, Doubling Its Drug Royalty Portfolio
Ligand buys Xoma for $740M cash, boosting its drug royalty portfolio to 200+ medicines and spreading investment risk.
/ 2 items
Ligand buys Xoma for $740M cash, boosting its drug royalty portfolio to 200+ medicines and spreading investment risk.
Wells Fargo upgrades Monte Rosa Therapeutics on 2026 catalysts, while Jefferies downgrades Generation Bio due to its pending acquisition by Xoma.